Floatz logo

Epi-743

Pearson Syndrome

Edison Pharmaceuticals IncPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Pearson Syndrome cohort.

Asset / SponsorPhaseRating
Mnv-201
Minovia Therapeutics Ltd.
Phase 2CCC
MNV-BLD
Minovia Therapeutics Ltd.
Phase 1/2CCC

Same molecule, other indications

Epi-743 is also rated in:

Friedreich ataxiaDormant
B
Indicative ·
62 / 100
View asset →
Leigh syndromeDormant
B
Indicative ·
62 / 100
View asset →
Parkinson diseaseDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →